The new drug "Jakavi", produced by the Swiss company "Novartis", is well-known among doctors involved in the treatment of cancer.
Ruxolitinib, which is the main active ingredient of the named product, is a protein tyrosine kinase inhibitor. It is effective in the treatment of diseases that are associated with splenomegaly, as well as myelofibrosis (including primary and secondary, developed as a result of essential thrombocythemia and true polycythemia).
Researchers note that the use of the drug reduced the size of the spleen by 35%, increased life expectancy and its quality. In this case, the toxicity of the active substance is moderate, in comparison with other drugs of a similar spectrum of action.
Where can I buy Jakavi tablets cheaper
But before continuing with the description of the drug, one cannot fail to say that the treatment of serious diseases requires a large number of expensive drugs, and this cannot but cause concern in patients. It is not possible to refuse vital medicines, but it is often quite difficult to acquire them. So, in Moscow pharmacies, the price of Jakavi tablets starts from 100,000 rubles.
The site can come to the rescue in this situation where you can get a generic drug called . With the complete similarity of the components and the same effect from the application, it will cost much cheaper. The fact is that the production of generics does not bear the costs of developing, testing and promoting the product, which allows its manufacturers working under an official license to pay for the release of the drug at a lower cost.
Dosage and dosage
Patients should be aware that the use of the drug "Jakavi" is not dependent on food intake. And if at the prescribed time it was not possible to drink the tablets, then you can not take their double dose. Because of this, you should not shift the time of the next dose.
The initial dose of the described drug is prescribed only by a specialist, depending on the blood counts - the number of platelets. As a rule, it is 15 mg (take 2 r. Per day), with their number 100-200 / nl, and with an amount of more than 200 / nl - 20 mg. If the platelet count is 50-100 / nl, then the maximum initial dose should not be more than 5 mg, twice a day. Moreover, the maximum dose, according to the instructions for use attached to the drug "Jakavi", should not exceed 25 mg taken twice a day.
In general, in the treatment with ruxolithinib, regular blood counts of the formed elements (erythrocytes, leukocytes and platelets) should be carried out: every 2-4 weeks during the dose selection period and then depending on the clinical indications.
Contraindications
There are certain contraindications for using the Jakavi preparation:
- Pregnancy and lactation.
- Patient is under eighteen years old.
- Personal intolerance to ruxolitinib or other component of the drug.
As the reviews of specialists on the use of Jakawi say, the drug should be used with caution to treat patients with renal failure or undergoing hemodialysis. Patients with thrombocytopenia, neutropenia, and anemia fall into the same category.
Side effects
During the application, as indicated by the instructions attached to the Jakavi, the following adverse reactions were most often observed:
- urinary tract infections;
- anemia;
- neutrophilia;
- thrombocytopenia;
- bleeding (including bruising, nasal and intracranial bleeding, as well as hemorrhage in the digestive tract);
- weight gain;
- Dizziness
- hypercholesterolemia;
- headache.